🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Cabotegravir Injectable Suspension (CAB LA)

Found 15 matching trials

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

PHASE3

The purpose of this study is to evaluate if offering long-acting injectable...

Status

Not Yet Recruiting

Location

Hôpital Hôtel Dieu

Start Date

2024-04-01

Trial ID

NCT06273943

Treatments Being Tested

Cabotegravir Tablets, for oral use.Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use Rectal Biopsies

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

PHASE3

This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLA...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2017-10-27

Trial ID

NCT03299049

Treatments Being Tested

Cabotegravir Tablets Rilpivirine Tablets Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension

Oregon PrEP at Home Study

N/A

This demonstration study will evaluate the real-world implementation of lon...

Status

Unknown

Location

Oregon Health & Science University

Start Date

2023-12-01

Trial ID

NCT05949203

Treatments Being Tested

Cabotegravir Injection

Long-Acting Treatment in Adolescents (LATA)

PHASE3

The LATA trial will find out if taking a long-acting injectable form of HIV...

Status

Unknown

Location

Moi University

Start Date

2023-06-22

Trial ID

NCT05154747

Treatments Being Tested

Cabotegravir, Rilpivirine Drug Combination TLD

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

PHASE3

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is bein...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-28

Trial ID

NCT02951052

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)2 NRTIs plus an INI, NNRTI, or PI

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

PHASE3

This study will assess the pharmacokinetics, safety, tolerability, maintena...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-11-08

Trial ID

NCT05896748

Treatments Being Tested

Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

PHASE3

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted t...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-27

Trial ID

NCT02938520

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)ABC/DTG/3TC STR - Tablet DTG Tablet

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

PHASE3

This study is designed to assess the antiviral activity and safety of a two...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-11-09

Trial ID

NCT04542070

Treatments Being Tested

Cabotegravir Tablets Cabotegravir Injectable Suspension (CAB LA)Rilpivirine Tablets Rilpivirine Injectable Suspension (RPV LA)BIKTARVY Tablets (BIK)

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

PHASE1

The pre-exposure prophylaxis (PrEP) is an important component in the overal...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-04-10

Trial ID

NCT03422172

Treatments Being Tested

Oral CAB CAB LA

Previous Next